Virax Biolabs Group Ltd. Class A (VRAX) has released an update.
Virax Biolabs Group Ltd. has announced the potential issuance and sale of up to $2,879,117 worth of ordinary shares through an at-the-market offering. This offering is facilitated by H.C. Wainwright & Co. under an agreement dated January 22, 2024, and forms part of a previously filed and effective registration statement. The company has provided legal opinions and examined various documents to support the issuance, ensuring compliance with Cayman Islands laws and corporate governance.
For further insights into VRAX stock, check out TipRanks’ Stock Analysis page.
